Humana Inc. (HUM) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Per the Roarable RQD rating, HUM scores 64 out of 100, a letter grade of C, with the verdict "Roarable Hold — Fair / Balanced Risk-Reward." The five pillars are:

• Fundamental Cash Engine: 9 / 20. Per the RQD rating this reflects ROIC of 8.3% and an FCF yield of 0.75%. Cash generation is the weakest part of the thesis relative to the stock's valuation.
• Whale 13F Flow: 16 / 20. Per the RQD rating, this pillar captures institutional accumulation and options positioning, and is among the stronger scores.
• Insider Conviction: 9 / 20. Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow and is comparatively weak.
• Macro Regime Fit: 12 / 20. Per the RQD rating, this reflects a beta of 0.88 and sector sensitivity; the stock's low beta is a defensive attribute, but the pillar score is middling.
• Forensic Balance Sheet: 18 / 20. Per the RQD rating, Altman Z of 5.03, Piotroski F of 7/9, and Debt/Equity of 0.7 make this the strongest pillar.

For a prospective investor evaluating the stock today, the rating points to a balanced setup rather than a clear-cut opportunity. The upside case rests on balance-sheet strength and institutional interest. The valuation tradeoff is significant: per the market data, the trailing P/E is 42.2 and the forward P/E is 39.2, while FCF yield is only 0.75%, meaning the price embeds expectations that current free-cash generation does not yet cover. Investors should weigh whether the earnings recovery implied by forward multiples materializes before treating the rating as a constructive signal.

Humana Inc. is a NYSE-listed issuer in the Health Care sector and the Medical Specialities industry, per the profile. Per the SEC financials, the company reported FY 2025 revenue of $129664.0M. Per the profile, the source data does not itemize its products, customer segments, or revenue streams beyond sector and industry classification. Not available in source data for detailed business model descriptions.

Per the SEC financials, revenue grew from $106374.0M in FY 2023 to $129664.0M in FY 2025, while net income declined from $2489.0M to $1188.0M over the same span. Per the market data, the operating margin is 2.1%, the net margin is 0.9%, and the gross margin is listed as 0%. Per the market data, ROIC is 8.3%. Per the RQD rating, the Altman Z-Score is 5.03 and the Piotroski F-Score is 7/9, and Debt/Equity is 0.7. Per the SEC financials, FY 2025 debt of $12369.0M is well below the FY 2023 figure of $29869.8M, and cash rose to $4200.0M.

Per the recent news feed, the most recent items are tagged as catalysts or market-wire items. Catalyst-tagged headlines reference the Medicare Advantage star ratings: "Humana Stock Jumps on Raised Medicare Advantage Ratings" (Investopedia, GREEN) and "Humana stock rises 15% after Medicare quality ratings jump" (Quartz, GREEN). Market-wire items include "Humana's Star Ratings Progress Doesn't Erase Valuation Concerns" (Seeking Alpha, YELLOW), which flags valuation as a counterweight to the ratings improvement, and "Humana (HUM) Stock Trades Up, Here Is Why" (Yahoo Finance, YELLOW). Risk watch: the Seeking Alpha headline explicitly names valuation concerns. Proprietary signals: Not available in source data; the Butterfly Supply-Chain Graph lists no proprietary signals.